COVID-19 and Asthma: Reflection During the Pandemic.
Clin Rev Allergy Immunol
; 59(1): 78-88, 2020 Aug.
Article
in English
| MEDLINE | ID: covidwho-1139385
ABSTRACT
Coronavirus disease 2019 (COVID-19) is a global pandemic infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and abnormal, overactivated innate immunity and "cytokine storms" have been proposed as potential pathological mechanisms for rapid COVID-19 progression. Theoretically, asthmatic patients should have increased susceptibility and severity for SARS-CoV-2 infection due to a deficient antiviral immune response and the tendency for exacerbation elicited by common respiratory viruses. However, existing studies have not shown an expected prevalence of asthmatic individuals among COVID-19 patients. Certain aspects of type 2 immune response, including type 2 cytokines (IL-4, IL-13, etc.) and accumulation of eosinophils, might provide potential protective effects against COVID-19. Furthermore, conventional therapeutics for asthma, including inhaled corticosteroids, allergen immunotherapy (AIT), and anti-IgE monoclonal antibody, might also reduce the risks of asthmatics suffering infection of the virus through alleviating inflammation or enhancing antiviral defense. The interactions between COVID-19 and asthma deserve further attention and clarification.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Asthma
/
Coronavirus Infections
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Clin Rev Allergy Immunol
Journal subject:
Allergy and Immunology
Year:
2020
Document Type:
Article
Affiliation country:
S12016-020-08797-3
Similar
MEDLINE
...
LILACS
LIS